Skip to main content

Table 3 Subjects baseline characteristics

From: Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab

Number of subjects 25
Median age in yrs (range) 7.4 (4.5-15.4)
Male 19 (76%)
Clinical reaction
  Respiratory 5 (20%)
  Gastro-intestinal 13 (52%)
  Epinephrine 1 (4%)
Number of foods dosed
  2 7 (28%)
  3 4 (16%)
  4 7 (28%)
  5 7 (28%)
Peanut baseline allergy test (if included in mix) (median and range)
  SPT in mm 13 (3.5-26)
  Specific IgE in kUa/L 31 (1–192)
  Lowest amount triggering reaction in DBPCFC in mg protein 15.5 (1.6-100)
Highest baseline allergy test (median and range)
  SPT in mm 17 (6–29.5)
  Specific IgE in kUa/L 66 (2–256)
  Lowest amount triggering reaction in DBPCFC in mg protein 6 (0.1-100)
Total IgE in kuA/L (median and range) 645 (67–1829)